SecProbe.io

CORRESP
1
filename1.htm

China Health Industries
Holdings, Inc.

3199-1 Longxiang Road,
Songbei District

Harbin City, Heilongjiang
Province

People’s Republic
of China, 150028

January 19, 2024

VIA EDGAR TRANSMISSION

United States Securities and Exchange Commission

Division of Corporation Finance

Disclosure Review Program

100 F Street NE

Washington, D.C. 20549

Attn: Charlie Guidry and Christopher Dunham

    Re:
    China Health Industries Holdings, Inc.

    Form 10-K for Fiscal Year Ended June 30, 2023

    File No. 000-51060

Dear Messrs. Guidry and Dunham:

This letter is being
furnished in response to the comment of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and
Exchange Commission (the “Commission”) that was contained in the Staff’s letter dated January 9, 2024, to China Health
Industries Holdings, Inc (the “Company”) with respect to the Company’s Annual Report on Form 10-K (the “10-K”)
for the fiscal year ended June 30, 2023 filed with the Commission on November 13, 2023 (File No. 001-51060) and the Supplemental Submission
form “SPDSCL-HFCAA-GOV” filed with the Commission on January 8, 2024.

Set forth below is the
Company’s response to the Staff’s comment. For ease of reference, the Staff’s comment is reproduced below and is followed
by the Company’s response in bold.

Form 10-K for Fiscal Year Ended June 30, 2023

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent
Inspections, page 30

 1. We note your statement that you reviewed your shareholders' list in connection
with your required submission under paragraph (a). Please supplementally describe any additional materials that were reviewed and tell
us whether you relied upon any legal opinions or third party certifications such as affidavits as the basis for your submission.

Response: The Company has reviewed the
registered shareholder’s list as of September 28, 2023 issued by its transfer agent. To the knowledge of the management, no shareholder
is an official of the Chinese government. The management also reviewed the ownership filings via Edgar and do not find any filings made
by any official of the Chinese government.

Should any questions arise in
connection with this response letter, please contact Elizabeth F. Chen, Esq. from Pryor Cashman LLP, counsel to the Company at 212-326-0199
or echen@pryorcashman.com.

    Sincerely yours,

    China Health Industries Holding, Inc.

    /s/ Xin Sun

    Xin Sun

    Chief Executive Officer and

                                    Chief Financial Officer

    (Principal Executive Officer,

                                 Principal Financial Officer and

                                 Principal Accounting Officer)

    cc:

    Elizabeth F. Chen, Esq.

    Pryor Cashman LLP